
News|Articles|July 2, 2025
FDA Backs Shield Test for Broad Early Cancer Screening: Daily Dose
Author(s)Sydney Jennings
Your daily dose of the clinical news you may have missed.
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On June 4, 2025, we reported that the US FDA granted Breakthrough Device designation to the Shield multi-cancer detection (MCD) test (Guardant Health).
The approval
Supporting the breakthrough designation, Guardant presented clinical validation data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating the test’s high specificity, robust sensitivity, and accurate identification of cancer signal origin (CSO) across a range of tumor types. In a blinded, case-control study of 962 participants, the test achieved an overall specificity of 98.6% and a sensitivity of 59.7% across the 10 cancer types included in the CSO model. Primary or secondary CSO prediction was 92% accurate for those cancers.
The Shield test uses a next-generation sequencing-based epigenomic hybrid capture assay to measure DNA methylation patterns associated with malignancy. A 2-stage classification algorithm first distinguishes cancer from non-cancer samples and then predicts the tissue of origin for cancer-positive cases.
A prospective interventional study is currently underway to evaluate real-world feasibility, and the test has also been selected for use in the National Cancer Institute’s Vanguard Study, a large-scale evaluation of emerging MCD technologies.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Semaglutide CV Effects Appear Independent of Baseline Adiposity, Suggesting Disease-Modifying Potential
2
Elinzanetant Improves Sleep Through VMS-Independent Mechanisms, According to New Pooled Analysis
3
Topline Real-World Data Show Fezolinetant Improves VMS, Sleep, and Work Productivity in Women With Confirmed Menopausal VMS
4
APOE ε4 and Inflammation Amplify Risk for Memory Decline in Women with Earlier Menopause
5